OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • November 1st, 2022 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
11,000,000 Shares AURA BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 9th, 2023 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
FORM OF DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • October 25th, 2021 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ] by and between Aura Biosciences, Inc., a Delaware corporation, together with its subsidiaries, (the “Company”), and [Director] (“Indemnitee”).
LEASE DATED: AS OF JUNE 9, 2011 BOLTON STREET PARTNERS, LLC, LESSOR AURA BIOSCIENCES, INC, LESSEE 85-95 BOLTON STREET, CAMBRIDGE, MASSACHUSETTSLease • October 8th, 2021 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS LEASE is made as of the 9th day of June, 2011 by and between BOLTON STREET PARTNERS, LLC, a Massachusetts limited liability corporation with a place of business at 126 North Washington Street, Suite 5, Boston, Massachusetts 02114 (“Lessor”), and Aura Biosciences, Inc., a Connecticut corporation, with a principal place of business as of the date hereof at I Kendall Square, Building 600, Ste, B6101, Cambridge, MA 02139 (“Lessee”).
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Exclusive License and Supply Agreement • October 8th, 2021 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
This Exclusive License and Supply Agreement (this “Agreement”) is dated January 31, 2014 (“Effective Date”) and is between LI-COR, Inc., a Nebraska corporation with a principal address of 4647 Superior Street, Lincoln, Nebraska 68504 (“LI-COR”), and Aura Biosciences, Inc., a Delaware corporation with a principal address of 85 Bolton Street, Cambridge, MA 02140 (“Aura”). LI-COR and Aura individually referred to herein as a “Party” and collectively as the “Parties”.
LEASE BETWEEN AURA BIOSCIENCES, INC., AS TENANT ANDLease Agreement • August 11th, 2022 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances)
THIS LEASE is dated as of May 13, 2022 (the “Effective Date”), between the Landlord and the Tenant named below, and is of space in the Building described below.
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...License Agreement • October 8th, 2021 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • Georgia
THIS LICENSE AGREEMENT (the “Agreement”), effective as of July 3, 2019 (the “Effective Date”), is by and between Clearside Biomedical, Inc., a Delaware corporation having a principal place of business at 900 North Point Parkway, Suite 200, Alpharetta, GA 30005 (“Clearside”) and Aura Biosciences, Inc., a Delaware corporation having its principal place of business at 85 Bolton Street, Cambridge, MA 02140 (“Aura”).
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Patent License Agreement • October 8th, 2021 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
PERSONAL AND CONFIDENTIAL Dr. Cadmus Rich Re: Transition and Release Agreement Dear Dr. Rich:Transition and Release Agreement • November 9th, 2023 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This letter confirms your resignation from employment with Aura Biosciences, Inc. (the “Company”), effective November 7, 2023. As you know, your employment relationship with the Company is governed by your offer letter with the Company dated October 6, 2017 (the “Offer Letter”). As specified in Section 13 of the Offer Letter, you have been employed “at-will,” meaning that you or the Company could end the employment relationship at any time and for any reason, subject to the terms of the Offer Letter.
•] Shares AURA BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 25th, 2021 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
PERSONAL AND CONFIDENTIAL Dr. Cadmus Rich Re: Resignation and Consulting Agreement Dear Dr. Rich:Consulting Agreement • November 9th, 2023 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This letter confirms your resignation from your employment with Aura Biosciences, Inc. (the “Company”) effective on November 7, 2023 (the “Resignation Date”). The Company is also offering you the opportunity to enter into a consulting relationship with the Company following the Resignation Date. The terms of the consulting engagement, should you accept this offer, are set forth below (the “Consulting Agreement”).
AURA BIOSCIENCES, INC. FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT March 18, 2021Investors’ Rights Agreement • October 8th, 2021 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of March 18, 2021, by and among Aura Biosciences, Inc., a Delaware corporation (the “Company”) and the persons and entities listed on Schedule A hereto (each, an “Investor” and collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the meanings ascribed to them in Section 1.
6,700,000 Shares AURA BIOSCIENCES, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 5th, 2022 • Aura Biosciences, Inc. • Biological products, (no disgnostic substances)
